Sabolović D, Dubravcić D, Culo F, Hadzić N
Lijec Vjesn. 1989 Jun-Jul;111(6-7):185-7.
The concentration of histamine in blood was determined in 22 patients with solid malignant tumors, 16 hospitalized non-cancer patients and 9 healthy subjects. Patients with cancer (mainly carcinomas of the breast and gastrointestinal tract) were divided into two groups: patients with resected primary tumor without known metastases (group I) and patients with present primary tumor with or without metastases (group II). In comparison with the healthy subjects (histamine concentration 69.0 +/- 6.03 ng.ml-1), cancer patients in both groups had significantly decreased levels of histamine in blood. Also, the concentration of histamine in patients with present tumor (group II; 40.1 +/- 3.48 ng.ml-1) vas significantly lower than in patients with resected primary tumor (49.9 +/- 3.14 ng.ml-1). Furthermore, hospitalized non-cancer patients had lower, but not statistically significant, concentration of histamine (59.7 +/- 6.13 ng.ml-1) than healthy subjects. These findings, together with similar data of other authors, suggest that decreased level of histamine in blood might be a good nonspecific marker for onset and progression of solid malignant tumors.
对22例实体恶性肿瘤患者、16例住院非癌症患者和9名健康受试者的血液组胺浓度进行了测定。癌症患者(主要是乳腺癌和胃肠道癌)分为两组:原发性肿瘤已切除且无已知转移的患者(第一组)和存在原发性肿瘤且有或无转移的患者(第二组)。与健康受试者(组胺浓度为69.0±6.03 ng/ml)相比,两组癌症患者血液中的组胺水平均显著降低。此外,存在肿瘤的患者(第二组;40.1±3.48 ng/ml)的组胺浓度显著低于原发性肿瘤已切除的患者(49.9±3.14 ng/ml)。此外,住院非癌症患者的组胺浓度(59.7±6.13 ng/ml)低于健康受试者,但无统计学意义。这些发现,连同其他作者的类似数据,表明血液中组胺水平降低可能是实体恶性肿瘤发生和进展的良好非特异性标志物。